Long/Short Investments
All posts from Long/Short Investments
Long/Short Investments in L/S Equity: Valuation and Ideas,

​The Biggest Winner Post-Trump Victory

The far left’s demonization of pharmaceutical drug pricing practices generated anxiety among shareholders in the event of a Clinton victory in the US presidential election. Nonetheless, several drug companies skyrocketed out of the gate, largely with Mylan among the chief notable gainer after coming under fire after the EpiPen controversy.

Among other chief gainers:

TEVA -- +6%

PFE -- +5%

ABBV -- +4%

AGN -- +4%

AMGN -- +4%

CELG -- +3%

REGN -- +3%

NVS -- +3%

GILD -- +2%

MRK -- +2%